| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|--------------------------------------|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000 | 0 | |
| | | | | |

MERLIN - multivariate Mixed-Effects Regression for LInear, Non-linear and user defined models

Emma C. Martin, Alessandro Gasparini, Michael J. Crowther

Department of Health Sciences, University of Leicester, UK, emma.martin@le.ac.uk

Funding: MRC (MR/P015433/1)

| | The Motivation ●00 | The Goal 00 | The Example 000000000000000000000000000000000000 | The Future O | References |
|--|-----------------------|----------------|---|-----------------|------------|
|--|-----------------------|----------------|---|-----------------|------------|

| The Motivation ●00 | The Goal 00 | The Example | The Future O | References |
|-----------------------|----------------|-------------|-----------------|------------|
| | | | | |

Increasing access to big data such as electronic health records (EHRs)

| The Motivation ●00 | The Goal 00 | The Example | The Future 0 | References |
|-----------------------|----------------|-------------|-----------------|------------|
| | | | | |

Increasing access to big data such as electronic health records (EHRs)

multi-level (biomarkers < patients < GP practice area < geographical regions...)</p>

Increasing access to big data such as electronic health records (EHRs)

- multi-level (biomarkers < patients < GP practice area < geographical regions...)</p>
- multiple related outcomes (biomarkers, survival endpoints)

| The Motivation 0●0 | The Goal 00 | The Example | The Future O | References |
|-----------------------|----------------|-------------|-----------------|------------|
| | | | | |

Joint longitudinal survival models



Joint longitudinal survival models

- stjm in Stata (Crowther et al., 2013)
- gsem in Stata
- frailtypack in R (Rondeau et al., 2012)
- joineR and joineRML in R (Philipson et al., 2018; Hickey et al., 2018)
- ► JM and JMBayes in R (Rizopoulos, 2016)

| The Motivation 000 | The Goal ●0 | The Example 000000000000000000000000000000000000 | The Future 0 | References |
|-----------------------|----------------|---|-----------------|------------|
| | | | | |
| | | | | |

The Goal

We want to increase the flexibility of joint longitudinal survival models, including extensions:

- competing risks (Li et al., 2009)
- different types of outcomes (Rizopoulos et al., 2008)
- multiple continuous outcomes (Lin et al., 2002)
- delayed entry (Crowther et al., 2016)
- recurrent events and a terminal event (Krol et al., 2016)
- predictions (Barrett and Su, 2017)

| The Motivation 000 | The Goal 0● | The Example 000000000000000000000000000000000000 | The Future O | References |
|-----------------------|----------------|---|-----------------|------------|
| | | | | |
| | | | | |

MERLIN

- ► Tutorial paper in Stata (Crowther, 2018)
- www.mjcrowther.co.uk/software/merlin

| MICHAEL J. CROWTHER | Home | Publications | Software | Posts | Projects | Teaching | |
|-------------------------------------|---|-----------------|------------|----------|-----------|----------|--|
| Survival (time-to-event) analysis | | | | | | | |
| Parametric surv | vival mode | l with a frail | ty/randor | n intere | cept [Dra | ft] | |
| Parametric surv | • Parametric survival model with random coefficients [TBA] | | | | | | |
| Three-level sur | • Three-level survival models - IPD meta-analysis of recurrent event data | | | | | | |
| [Draft, Sim] | [Draft, Sim] | | | | | | |
| Royston-Parma | ar multilev | vel survival n | nodels [TI | BA] | | | |
| User-defined h | azard mod | lels – an exa | mple with | fractio | nal polyr | iomials | |
| [Tutorial] | | | | | | | |
| Interval-censor | red surviva | al analysis [ˈ] | [utorial] | | | | |
| • Individual patie | ent data ne | twork meta | -analysis | of surv | ival data | [TBA] | |

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---------------------------------------|------------|------------|
| 000 | 00 | ●000000000000000000000000000000000000 | 0 | |
| | | | | |

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---------------------|------------|------------|
| 000 | 00 | ••••••••••••••••••• | | |
| | | | | |

To illustrate the flexibility we will use a single dataset of patients with primary biliary cirrhosis

 312 patients with PBC collected at the Mayo Clinic 1974-1984 (Murtaugh et al., 1994)

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|--------------------------|------------|------------|
| 000 | 00 | •00000000000000000000000 | 0 | |

- 312 patients with PBC collected at the Mayo Clinic 1974-1984 (Murtaugh et al., 1994)
- 158 randomised to receive D-penicillamine and 154 to placebo

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|--------------------------|------------|------------|
| 000 | 00 | •00000000000000000000000 | 0 | |

- 312 patients with PBC collected at the Mayo Clinic 1974-1984 (Murtaugh et al., 1994)
- 158 randomised to receive D-penicillamine and 154 to placebo
- ▶ survival outcome is all-cause death, with 140 events

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|--------------------------|------------|------------|
| 000 | 00 | •00000000000000000000000 | 0 | |

- 312 patients with PBC collected at the Mayo Clinic 1974-1984 (Murtaugh et al., 1994)
- 158 randomised to receive D-penicillamine and 154 to placebo
- ▶ survival outcome is all-cause death, with 140 events
 - We will simulate competing risks of death for illustration

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|--------------------------|------------|------------|
| 000 | 00 | •00000000000000000000000 | | |

- 312 patients with PBC collected at the Mayo Clinic 1974-1984 (Murtaugh et al., 1994)
- 158 randomised to receive D-penicillamine and 154 to placebo
- ▶ survival outcome is all-cause death, with 140 events
 - ▶ We will simulate competing risks of death for illustration
- 1945 repeated measurements of serum bilirubin, as well as other longitudinal biomarkers

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---------------------------|------------|------------|
| 000 | 00 | •000000000000000000000000 | 0 | |

- 312 patients with PBC collected at the Mayo Clinic 1974-1984 (Murtaugh et al., 1994)
- 158 randomised to receive D-penicillamine and 154 to placebo
- ▶ survival outcome is all-cause death, with 140 events
 - ► We will simulate competing risks of death for illustration
- 1945 repeated measurements of serum bilirubin, as well as other longitudinal biomarkers
- a formatted version of this data set is included in the merlin package in R

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000000 | | |

| | id | stime | died | cancer | other | trt | time | logb | logp |
|----|----|-------|------|--------|-------|-----|-------|--------|-------|
| 1 | 1 | 1.095 | 1 | 1 | 0 | 1 | 0.000 | 2.674 | 2.501 |
| 2 | 1 | NA | NA | NA | NA | 1 | 0.526 | 3.059 | 2.416 |
| 3 | 3 | 2.771 | 1 | 0 | 1 | 1 | 0.000 | 0.336 | 2.485 |
| 4 | 3 | NA | NA | NA | NA | 1 | 0.482 | 0.095 | 2.485 |
| 5 | 3 | NA | NA | NA | NA | 1 | 0.997 | 0.405 | 2.485 |
| 6 | 3 | NA | NA | NA | NA | 1 | 2.034 | 0.588 | 2.588 |
| 7 | 7 | 6.848 | 0 | 0 | 0 | 0 | 0.000 | 0.000 | 2.272 |
| 8 | 7 | NA | NA | NA | NA | 0 | 1.073 | 0.182 | 2.370 |
| 9 | 7 | NA | NA | NA | NA | 0 | 1.492 | -0.223 | 2.370 |
| 10 | 7 | NA | NA | NA | NA | 0 | 2.081 | 0.000 | 2.332 |
| 11 | 7 | NA | NA | NA | NA | 0 | 3.083 | 0.182 | 2.389 |
| 12 | 7 | NA | NA | NA | NA | 0 | 4.077 | 0.182 | 2.434 |
| 13 | 7 | NA | NA | NA | NA | 0 | 6.193 | 0.336 | 2.485 |

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000000 | | |

| | id | stime | died | cancer | other | trt | time | logb | logp |
|----|----|-------|------|--------|-------|-----|-------|--------|-------|
| 1 | 1 | 1.095 | 1 | 1 | 0 | 1 | 0.000 | 2.674 | 2.501 |
| 2 | 1 | NA | NA | NA | NA | 1 | 0.526 | 3.059 | 2.416 |
| 3 | 3 | 2.771 | 1 | 0 | 1 | 1 | 0.000 | 0.336 | 2.485 |
| 4 | 3 | NA | NA | NA | NA | 1 | 0.482 | 0.095 | 2.485 |
| 5 | 3 | NA | NA | NA | NA | 1 | 0.997 | 0.405 | 2.485 |
| 6 | 3 | NA | NA | NA | NA | 1 | 2.034 | 0.588 | 2.588 |
| 7 | 7 | 6.848 | 0 | 0 | 0 | 0 | 0.000 | 0.000 | 2.272 |
| 8 | 7 | NA | NA | NA | NA | 0 | 1.073 | 0.182 | 2.370 |
| 9 | 7 | NA | NA | NA | NA | 0 | 1.492 | -0.223 | 2.370 |
| 10 | 7 | NA | NA | NA | NA | 0 | 2.081 | 0.000 | 2.332 |
| 11 | 7 | NA | NA | NA | NA | 0 | 3.083 | 0.182 | 2.389 |
| 12 | 7 | NA | NA | NA | NA | 0 | 4.077 | 0.182 | 2.434 |
| 13 | 7 | NA | NA | NA | NA | 0 | 6.193 | 0.336 | 2.485 |

| Emmal | Martin | |
|-------|--------|--|
| | | |

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000000 | | |

| | id | stime | died | cancer | other | trt | time | logb | logp |
|----|----|-------|------|--------|-------|-----|-------|--------|-------|
| 1 | 1 | 1.095 | 1 | 1 | 0 | 1 | 0.000 | 2.674 | 2.501 |
| 2 | 1 | NA | NA | NA | NA | 1 | 0.526 | 3.059 | 2.416 |
| 3 | 3 | 2.771 | 1 | 0 | 1 | 1 | 0.000 | 0.336 | 2.485 |
| 4 | 3 | NA | NA | NA | NA | 1 | 0.482 | 0.095 | 2.485 |
| 5 | 3 | NA | NA | NA | NA | 1 | 0.997 | 0.405 | 2.485 |
| 6 | 3 | NA | NA | NA | NA | 1 | 2.034 | 0.588 | 2.588 |
| 7 | 7 | 6.848 | 0 | 0 | 0 | 0 | 0.000 | 0.000 | 2.272 |
| 8 | 7 | NA | NA | NA | NA | 0 | 1.073 | 0.182 | 2.370 |
| 9 | 7 | NA | NA | NA | NA | 0 | 1.492 | -0.223 | 2.370 |
| 10 | 7 | NA | NA | NA | NA | 0 | 2.081 | 0.000 | 2.332 |
| 11 | 7 | NA | NA | NA | NA | 0 | 3.083 | 0.182 | 2.389 |
| 12 | 7 | NA | NA | NA | NA | 0 | 4.077 | 0.182 | 2.434 |
| 13 | 7 | NA | NA | NA | NA | 0 | 6.193 | 0.336 | 2.485 |

| Emma Martin | MERI |
|-------------|------|
|-------------|------|

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000000 | | |
| | | | | |

Longitudinal biomarker - linear model

```
merlin(
model = logb ~ time,
timevar = "time",
family = "gaussian",
data = pbc)
```

Longitudinal biomarker - restricted cubic splines

```
merlin(
model = logb ~ rcs(time, df = 3),
timevar = "time",
family = "gaussian",
data = pbc)
```

| 000 00 00000000000000000000000000000000 | The Motivation | The Goal | The Example | The Future | References |
|---|----------------|----------|---|------------|------------|
| | 000 | 00 | 000000000000000000000000000000000000000 | 0 | |

Longitudinal biomarker - random intercept

```
merlin(
model = logb ~ rcs(time, df = 3) + M1[id]*1,
level = "id",
timevar = "time",
family = "gaussian",
data = pbc)
```

| 000 00 0000000000000000 0 | The Motivation | The Goal | The Example | The Future | References |
|----------------------------------|----------------|----------|---|------------|---|
| | 000 | 00 | 000000000000000000000000000000000000000 | 0 | <u>. </u> |

Longitudinal biomarker - random slope

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000000 | | |

Longitudinal biomarker - covariance structure



Joint longitudinal-survival model

A number of time-to-event models are available in merlin, including standard models such as

- Weibull
- Exponential
- ► Gompertz



Joint longitudinal-survival model

A number of time-to-event models are available in merlin, including standard models such as

- ► Weibull
- Exponential
- Gompertz

Additionally a range of more flexible models are also available including

- Royston-Parmar restricted cubic splines on log cumulative hazard scale
- Restricted cubic splines on log hazard scale

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000000 | | |

Joint model - survival submodel

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|--------------------------------------|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000 | 0 | |
| | | | | |

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|--------------------------------------|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000 | 0 | |
| | | | | |

| The Motivation | The Goal 00 | The Example oooooooooooooooooooooooooo | The Future 0 | References |
|----------------|----------------|---|-----------------|------------|
| | | | | |

| The Motivation | The Goal 00 | The Example oooooooooooooooooooooooooo | The Future ⊙ | References |
|----------------|----------------|---|-----------------|------------|
| | | | | |

| The Motivation | The Goal 00 | The Example oooooooooooooooooooooooooo | The Future 0 | References |
|----------------|----------------|---|-----------------|------------|
| | | | | |

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000000 | 0 | |

Joint model - time dependent effects

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000000 | | |

Joint model - competing risks

```
merlin(
model = list(logb \sim rcs(time, df = 3) + M1[id]*1
                 + time:M2[id]*1,
              Surv(stime, cancer) \sim trt + EV[logb]
                 + trt:fp(stime, powers = c(0)),
              Surv(stime, other) \sim trt + dEV[logb]
                 + rcs(stime, df = 3, log = T)),
level = "id".
timevar = c("time", "stime"),
family = c("gaussian", "weibull", "rp"),
covariance = "unstructured",
data = pbc)
```

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000000 | | |

Joint model - competing risks

```
merlin(
model = list(logb \sim rcs(time, df = 3) + M1[id]*1
                 + time:M2[id]*1,
              Surv(stime, cancer) \sim trt + EV[logb]
                 + trt:fp(stime, powers = c(0)),
              Surv(stime, other) \sim trt + dEV[logb]
                 + rcs(stime, df = 3, log = T)),
level = "id".
timevar = c("time", "stime"),
family = c("gaussian", "weibull", "rp"),
covariance = "unstructured",
data = pbc)
```

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000000 | | |

Joint model - multiple biomarkers

```
merlin(
model = list(logb \sim rcs(time, df = 3) + M1[id]*1
                 + time:M2[id]*1,
              logp \sim rcs(time, df = 3) + M3[id]*1,
              Surv(stime, cancer) \sim trt + EV[logb]
                 + trt:fp(stime, powers = c(0)),
              Surv(stime, other) \sim trt + dEV[logb]
                 + rcs(stime, df = 3, log = T)),
level = "id".
timevar = c("time", "stime"),
family = c("gaussian", "gaussian", "weibull", "rp"),
covariance = "unstructured",
data = pbc)
```

| The Motivation | The Goal 00 | The Example 000000000000000000000000000000000000 | The Future 0 | References |
|----------------|----------------|---|-----------------|------------|
| | | | | |

Joint model - multiple biomarkers

```
merlin(
model = list(logb \sim rcs(time, df = 3) + M1[id]*1
                 + time:M2[id]*1.
              logp \sim rcs(time, df = 3) + M3[id]*1,
              Surv(stime, cancer) \sim trt + EV[logb]
                 + EV[logp] + iEV[logp]
                 + trt:fp(stime, powers = c(0)),
              Surv(stime, other) \sim trt + dEV[logb]
                 + rcs(stime, df = 3, log = T)),
level = "id",
timevar = c("time", "stime"),
family = c("gaussian", "gaussian", "weibull", "rp"),
covariance = "unstructured",
data = pbc)
```

| The Motivation | The Goal 00 | The Example 000000000000000000000000000000000000 | The Future 0 | References |
|----------------|----------------|---|-----------------|------------|
| | | | | |

Joint model - final model

```
merlin(
model = list(logb \sim rcs(time, df = 3) + M1[id]*1
                 + time:M2[id]*1.
              logp \sim rcs(time, df = 3) + M3[id]*1,
              Surv(stime, cancer) \sim trt + EV[logb]
                 + EV[logp] + iEV[logp]
                 + trt:fp(stime, powers = c(0)),
              Surv(stime, other) \sim trt + dEV[logb]
                 + rcs(stime, df = 3, log = T)),
level = "id",
timevar = c("time", "stime"),
family = c("gaussian", "gaussian", "weibull", "rp"),
covariance = "unstructured",
data = pbc)
```

Clinically meaningful predictions

e.g. using the predict function we can calculate the marginal cause-specific cumulative incidence function, which tells us the probability of an event in the presence of competing events,

Using the marginal option allows us to interpret them as population-average predictions.

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|---|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000000 | | |

Clinically meaningful predictions

We can specify the level of a covariate, in order to investigate the effect of covariates (such as treatment) on predictions



Treated group

| The Motivation | The Goal | The Example | The Future | References |
|----------------|----------|--------------------------------------|------------|------------|
| 000 | 00 | 000000000000000000000000000000000000 | ● | |
| | | | | |

The future

- Dynamic risk prediction
- Timing of observations informative observation process (Gasparini et al., 2018)
- merlin is very flexible, and hence it can be slow(er)
- Penalisation
- Scalability sample weights
- Updates and tutorials are available on the website www.mjcrowther.co.uk/software/merlin

| The Motivation | The Goal 00 | The Example | The Future 0 | References |
|----------------|----------------|-------------|-----------------|------------|
| | | | | |

References I

- Barrett, J. and Su, L. Dynamic predictions using flexible joint models of longitudinal and time-to-event data. *Statistics in Medicine*, 36(9):1447–1460, 2017.
- Crowther, M. J. merlin a unified modelling framework for data analysis and methods development in Stata. *arXiv e-prints*, art. arXiv:1806.01615, Jun 2018.
- Crowther, M. J., Abrams, K. R., and Lambert, P. C. Joint modeling of longitudinal and survival data. *Stata Journal*, 13(1):165–184, 2013.
- Crowther, M. J., Andersson, T. M., Lambert, P. C., Abrams, K. R., and Humphreys, K. Joint modelling of longitudinal and survival data: incorporating delayed entry and an assessment of model misspecification. *Stat Med*, 35(7):1193–209, 2016.
- Gasparini, A., Abrams, K. R., Barrett, J. K., Major, R. W., Sweeting, M. J., Brunskill, N. J., and Crowther, M. J. Mixed effects models for healthcare longitudinal data with an informative visiting process: a Monte Carlo simulation study. arXiv e-prints, art. arXiv:1808.00419, Aug 2018.
- Hickey, G. L., Philipson, P., Jorgensen, A., and Kolamunnage-Dona, R. joineRML: a joint model and software package for time-to-event and multivariate longitudinal outcomes. *BMC Medical Research Methodology*, 18(1):50, 2018.

| The Motivation | The Goal 00 | The Example 000000000000000000000000000000000000 | The Future 0 | References | | |
|----------------|----------------|---|-----------------|------------|--|--|
| | | | | | | |
| | | | | | | |
| References II | | | | | | |

- Krol, A., Ferrer, L., Pignon, J. P., Proust-Lima, C., Ducreux, M., Bouche, O., Michiels, S., and Rondeau, V. Joint model for left-censored longitudinal data, recurrent events and terminal event: Predictive abilities of tumor burden for cancer evolution with application to the ffcd 2000-05 trial. *Biometrics*, 72(3):907–16, 2016.
- Li, N., Elashoff, R. M., and Li, G. Robust joint modeling of longitudinal measurements and competing risks failure time data. *Biom J*, 51(1):19–30, 2009.
- Lin, H., McCulloch, C. E., and Mayne, S. T. Maximum likelihood estimation in the joint analysis of time-to-event and multiple longitudinal variables. *Stat Med*, 21 (16):2369–82, 2002.
- Murtaugh, P. A., Dickson, E. R., Vandam, G. M., Malinchoc, M., Grambsch, P. M., Langworthy, A. L., and Gips, C. H. Primary biliary-cirrhosis - prediction of short-term survival based on repeated patient visits. *Hepatology*, 20(1):126–134, 1994.
- Philipson, P., Sousa, I., Diggle, P. J., Williamson, P., Kolamunnage-Dona, R., Henderson, R., and Hickey, G. L. *joineR: Joint Modelling of Repeated Measurements and Time-to-Event Data*, 2018.
- Rizopoulos, D. The r package jmbayes for fitting joint models for longitudinal and time-to-event data using mcmc. *Journal of Statistical Software*, 72(7):1–46, 2016.

| The Motivation | The Goal 00 | The Example | The Future 0 | References |
|----------------|----------------|-------------|-----------------|------------|
| | | | | |

References III

- Rizopoulos, D., Verbeke, G., Lesaffre, E., and Vanrenterghem, Y. A two-part joint model for the analysis of survival and longitudinal binary data with excess zeros. *Biometrics*, 64(2):611–9, 2008.
- Rondeau, V., Mazroui, Y., and Gonzalez, J. R. frailtypack: An r package for the analysis of correlated survival data with frailty models using penalized likelihood estimation or parametrical estimation. *Journal of Statistical Software*, 47(4):1–28, 2012.